Calcium channel antagonists and inhibition of human sphincter of Oddi contractions

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 12, 2005, Pages 1394-1397

  Sand, Juhani ^a   Arvola, Pertti ^a   Nordback, Isto ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Calcium channel antagonist; Felodipine; Human sphincter of Oddi; Nifedipine; Smooth muscle contraction; Verapamil

Indexed keywords

ACETYLCHOLINE; CALCIUM CHANNEL BLOCKING AGENT; FELODIPINE; NIFEDIPINE; POTASSIUM CHLORIDE; VERAPAMIL;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN TISSUE; ODDI SPHINCTER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION;

CALCIUM CHANNEL BLOCKERS; FELODIPINE; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NIFEDIPINE; SPHINCTER OF ODDI; STIMULATION, CHEMICAL; TISSUE CULTURE TECHNIQUES; VERAPAMIL;

EID: 29744433117     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023800     Document Type: Article

References (28)

1. Calabuig R, Weems WA, Moody FG. Choledochoduodenal flow: effect of the sphincter of Oddi in opossums and cats. Gastroenterology 1990;99:1641-6.
2. Grace PA, Poston GJ, Williamson RCN. Biliary motility. GUT 1990;31:571-8.
3. Kinami Y, Ashida Y, Seto K, Takashima S, Kita I. Influence of incomplete bile duct obstruction on the occurrence of cholangiocarcinoma induced by disopropanolnitrosamine in hamsters. Oncology 1990;47:170-6.
4. Steinberg WM. Sphincter of Oddi dysfunction: a clinical controversy. Gastroenterology 1987;95:1409-15.
5. Toouli J, Geenen JE, Hogan WJ, Dodds WJ, Arndorfer RC. Sphincter of Oddi motor activity: a comparison between patients with common bile duct stones and controls. Gastroenterology 1982;82:111-7.
6. Guelrud M, Mendoza S, Rossiter G, Ramirez L, Barkin J. Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and in patients with biliary dyskinesia. Gastroenterology 1988;95:1050-5.
7. Sand J, Koskinen M, Nordback I. Cholescintigraphic evaluation of the effect of nifedipine upon bile drainage in patients suffering from Type II sphincter of Oddi dyskinesia. Hepatol Gastroenterol 1993;40:24-8.
8. Sand J, Nordback I, Koskinen M, Matikainen M, Lindholm TS. Nifedipine for Type II sphincter of Oddi dyskinesia. Am J Gastroenterol 1993;88:530-5.
9. Inkinen J, Sand J, Arvola P, Pörsti I, Nordback I. Direct effect of thyroxin on sphincter of Oddi contractility. Dig Dis Sci 2001;46:182-6.
10. Sand J, Arvola P, Jäntti V, Oja OS, Singaram C, Baer G, et al. The inhibitory role of nitric oxide in the control of porcine and human sphincter of Oddi activity. GUT 1997;41:375-80.
11. Sand J, Nordback I, Arvola P, Pörsti I, Kalloo A, Pasricha P. The effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study. GUT 1998;42:507-10.
12. Sand J, Arvola P, Pörsti I, Jäntti V, Oja S, Baer G, et al. Histamine in the control of porcine and human Sphincter of Oddi activity. Neurogastroenterol Motil 2000;12:573-9.
13. Bianciu T, Iova M, Biroacsiu G, Sucsan L. The diagnostic and therapeutic contribution of calcium channel inhibitors (nifedipine) in esophageal spasm. Med Intern 1990;28:69-71.
14. Celik AF, Katsinelos P, Read NW, Khan MI, Donnelly TC. Hereditary proctalgia fugax and constipation: report of a second family. Gut 1995;36:581-4.
15. George S, Pulimood S, Jacob M, Chandi SM. Pain in multiple leiomyomas alleviated by nifedipine. Pain 1997;73:101-2.
16. Sand JA, Frey T, Malminiemi K, Nordback IH. Nifedipine is not feasible for biliary pain in patients with gallbladder stones. Int J Clin Pharmacol Ther 1999;37:608-12.
17. Terry RW. Nifedipine therapy in angina pectoris: evaluation of safety and side effects. Am Heart 1982;104:681-9.
18. Ljung B. Vascular selectivity of felodipine: experimental pharmacology. J Cardiovasc Pharmacol 1990;15 Suppl 4:S11-6.
19. Blychert E, Hedner T, Dahlof C, Elmfeldt D. Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol 1990;15:428-35.
20. Larsson R, Karlberg BE, Gelin A, Aberg J, Regardh CG. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. J Clin Pharmacol 1990;30:1020-30.
21. Ahsan CH, Renwick AG, Waller DG, Challenor VF, Gearge CF, Amanullah M. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993;54:329-38.
22. Saseen JJ, Porter JA, Barnette DJ, Bauman JL, Zajac EJ Jr, Carter BL. J Clin Pharmacol 1997;37:526-34.
23. Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, et al. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol 1998;54:337-40.
24. Bar Meir S, Halpern Z, Bardan E. Nitrate therapy in a patient with papillary dysfunction. Am J Gastroenterol 1983;78:94-5.
25. Watson SJ, Kamm MA, Nicholls RJ, Phillips RK. Topical glyceryl trinitrate in the treatment of chronic anal fissure. Br J Surg 1996;83:771-5.
26. Fagan TC, Haggert BE, Liss C. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension. Clin Ther 1994;16:634-46.
27. Onwubere BJ, Obodo JO, Oke DA, Okeahialam BN, Danbauchi SS, Mbakwem AC. A randomized trial to compare the efficacy and safety of felodipine (Plendil) and nifedipine (Adalat) retard in patients with mild to moderate hypertension. West Afr J Med 2001;20:196-202.
28. De Leeuw PW, Birkenhager WH. The effects of calcium channel blockers on cardiovascular outcome: a review of randomized controlled trials. Blood Press 2002;11:71-8.